sorbitol has been researched along with Leishmaniasis, Visceral in 8 studies
D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).
Leishmaniasis, Visceral: A chronic disease caused by LEISHMANIA DONOVANI and transmitted by the bite of several sandflies of the genera Phlebotomus and Lutzomyia. It is commonly characterized by fever, chills, vomiting, anemia, hepatosplenomegaly, leukopenia, hypergammaglobulinemia, emaciation, and an earth-gray color of the skin. The disease is classified into three main types according to geographic distribution: Indian, Mediterranean (or infantile), and African.
| Excerpt | Relevance | Reference |
|---|---|---|
| "If not treated, visceral leishmaniasis is often fatal." | 1.28 | Chemotherapy of experimental visceral leishmaniasis in the opossum. ( Chapman, WL; Hanson, WL; White, MR, 1989) |
| " For both drugs, the data were best described by a two compartment, three term pharmacokinetic model representing an initial absorption phase with a mean half-life of 0." | 1.27 | Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate. ( Chulay, JD; Fleckenstein, L; Smith, DH, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coutellier, P | 1 |
| Delgrange, B | 1 |
| Chulay, JD | 1 |
| Fleckenstein, L | 1 |
| Smith, DH | 1 |
| White, MR | 1 |
| Chapman, WL | 1 |
| Hanson, WL | 1 |
| Kumar, PV | 1 |
| Sadeghi, E | 1 |
| Torabi, S | 1 |
| de la Cruz Amorós, E | 1 |
| Lambruschini Ferri, N | 1 |
| Rodríguez Miguélez, JM | 1 |
| Torres Simón, JM | 1 |
| Hiçsönmez, G | 1 |
| Jama, H | 1 |
| Ozsoylu, S | 1 |
| Verdejo, J | 1 |
| Alvar, J | 1 |
| Polo, RM | 1 |
| González-Lahoz, JM | 1 |
| Musumeci, S | 1 |
| Romeo, M | 1 |
| D'Agata, A | 1 |
8 other studies available for sorbitol and Leishmaniasis, Visceral
| Article | Year |
|---|---|
[Kala-azar. Apropos of a case report in a Belgian woman].
Topics: Antimony; Antiprotozoal Agents; Female; Humans; Leishmaniasis, Visceral; Meglumine; Meglumine Antimo | 1989 |
Pharmacokinetics of antimony during treatment of visceral leishmaniasis with sodium stibogluconate or meglumine antimoniate.
Topics: Antimony; Antimony Sodium Gluconate; Antiprotozoal Agents; Gluconates; Humans; Leishmaniasis, Viscer | 1988 |
Chemotherapy of experimental visceral leishmaniasis in the opossum.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; Body Weight; Female; Leishmaniasis, Visceral; Liver; | 1989 |
Kala azar with disseminated dermal leishmaniasis.
Topics: Adolescent; Antiprotozoal Agents; Biopsy; Child; Female; Humans; Iran; Leishmaniasis; Leishmaniasis, | 1989 |
[Glucantime and allopurinol in the treatment of persistent infantile visceral leishmaniasis].
Topics: Allopurinol; Humans; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunologic Tests; Infant | 1988 |
Severe leucopenia during treatment of visceral leishmaniasis.
Topics: Antimony; Antiprotozoal Agents; Child; Child, Preschool; Humans; Infant; Leishmaniasis, Visceral; Le | 1988 |
Glucantime-resistant visceral leishmaniasis in immunocompromised patients.
Topics: Antimony; Antiprotozoal Agents; Humans; Immune Tolerance; Leishmaniasis, Visceral; Meglumine; Meglum | 1988 |
Red cell survival and iron kinetics in kala-azar.
Topics: Amino Sugars; Anemia; Antimony; Antiprotozoal Agents; Bilirubin; Blood Volume; Child, Preschool; Chr | 1974 |